

Contents

Author biographies	ix
Abbreviations	xi
Foreword	xv
1 Introduction to ovarian cancer	1
Anatomy	1
Pathology	2
Epidemiology	4
Etiology	4
FIGO staging	6
Historic treatment paradigm – a model in evolution	7
Prognosis	9
References	10
2 Screening and prevention of ovarian cancer	11
Prevention of ovarian carcinoma	11
Screening for ovarian carcinoma	13
References	18
3 Clinical presentation and diagnostics	21
The adnexal mass	21
Triage of the adnexal mass	24
Presentation and evaluation of advanced disease	26
References	29
4 Managing the patient	31
Management of advanced stage ovarian carcinoma	31
Primary therapy of ovarian carcinoma	34
Landmark studies of primary therapy	38
Non-inferiority trials for primary therapy	41
Negative study in primary therapy	46
Indeterminate study in maintenance (consolidation) therapy	47

Management of recurrent disease	48
Landmark trials for recurrent disease	51
References	58
5 Translational science	61
Molecular genetics	61
<i>Breast cancer susceptibility genes</i> and carcinogenesis theory	65
Elucidation of crucial signal transduction pathways	68
Chemosensitivity testing	73
Angiogenesis	76
Poly (ADP-ribose) polymerase enzyme	79
References	81
6 Emerging therapies	83
Phase III randomized trials of anti-angiogenesis therapy	83
Targeting existing tumor vasculature	94
Hyperthermic intraperitoneal chemotherapy	95
Suicide bomb strategy	98
Targeted agents	101
Chemotherapy-free doublets	107
Immunotherapy	108
Gene signatures	111
References	112
7 Unique clinical scenarios	115
Epithelial ovarian cancer – five distinct diseases	115
Low-grade serous carcinoma	116
Newly diagnosed and recurrent mucinous carcinoma	117
Endometrioid carcinoma of the ovary	118
Newly diagnosed and recurrent clear cell carcinoma	118
Malignant germ cell tumors of the ovary	120
Sex cord stromal tumors of the ovary	121
Borderline tumors of the ovary	122
Fertility-preserving surgery	122
Ovarian cancer in pregnancy	123
Small cell carcinoma of the ovary	124
Pseudomyxoma peritonei	126

Krukenberg tumor	127
References	127
8 Supporting the patient	129
Important patient-oriented websites and contact information	129
Gynecologic Oncology Group (GOG) performance status scale	130
American Society of Clinical Oncology: growth factors CSF initiation, duration, dosing, and administration	131
Management of neutropenic fever	132
Opioids for cancer pain management	135
American Society of Clinical Oncology's 2011 antiemetics guideline update	136
Management of chemotherapy-induced constipation	138
Paclitaxel-associated hypersensitivity reaction	140
Carboplatin-delayed hypersensitivity reaction	141
Common agents for pain management in neuropathy	142
Preoperative bowel preparation	144
Perioperative venous thromboembolism prophylaxis	144
Therapeutic anticoagulation	145
American Society of Clinical Oncology: management of bone metastases	145
Management of limited (1–3) CNS metastases – recommendations from the National Comprehensive Cancer Network® (NCCN®)	146
Management of hypercalcemia of malignancy	147
References	147
Appendix	
A Evolution of cytoreductive surgery	149
A surgical masterpiece	151
Contemplations on an aggressive surgical approach	154
Proof of principle of cytoreduction	158
References	162
B Chemotherapy drugs and regimens	165
Chemotherapy drugs used for the treatment of ovarian cancer	165
References	177

C	Noteworthy clinical trials of historical interest	179
	Griffiths: impact of tumor bulk resection on survival in epithelial ovarian cancer	179
	'Early' ovarian cancer and surgical staging in epithelial ovarian cancer	179
	Gynecologic Oncology Group phase II BEP regimen for malignant germ cell tumors	180
	References	180
D	National and scientific milestones	181
	National and scientific milestones	181
	The war on cancer	183
	References	197
	Afterword	199

The 21st Century Handbook of Clinical Ovarian Cancer

Tewari, K.; Monk, B.

2015, XVI, 200 p. 63 illus., 44 illus. in color., Softcover

ISBN: 978-3-319-08065-9